secwatch.observer — SEC 8-K summary
======================================

Issuer:     ROCKET PHARMACEUTICALS, INC. (RCKT)
CIK:        0001281895
Form:       8-K
Filed at:   2022-03-11T23:59:59+00:00
Accession:  0001140361-22-009118
Event type: leadership
Sentiment:  negative
Materiality: 0.65
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Rocket Pharmaceuticals CFO resigns; appoints interim CFO and new director
-------------------------------------------------------------------------

- Fady Malik appointed to Board effective Mar 10; granted options for 33,199 shares (3-yr vest) and 8,641 shares (1-yr vest).
- CFO Carlos Garcia-Parada resigns effective Mar 16 due to personal reasons; will advise through Mar 31.
- John Militello, VP Finance and Controller, appointed interim Principal Financial Officer as of Mar 16.
- Dr. Malik is EVP R&D at Cytokinetics, cardiologist, clinical professor at UCSF.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1281895/000114036122009118/0001140361-22-009118-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1281895/000114036122009118/brhc10035116_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-22-009118

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer